IRIS
LOPETUSO, Loris Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.636
EU - Europa 1.317
AS - Asia 646
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 5
SA - Sud America 3
Totale 4.623
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.607
IE - Irlanda 476
SG - Singapore 361
IT - Italia 300
SE - Svezia 263
RU - Federazione Russa 106
CN - Cina 104
VN - Vietnam 93
DE - Germania 32
GB - Regno Unito 26
CA - Canada 23
IN - India 21
BE - Belgio 16
RO - Romania 16
TW - Taiwan 16
IR - Iran 13
FI - Finlandia 10
FR - Francia 9
BG - Bulgaria 8
PL - Polonia 8
TH - Thailandia 7
HK - Hong Kong 6
AU - Australia 5
EG - Egitto 5
EU - Europa 5
HR - Croazia 5
JP - Giappone 5
LU - Lussemburgo 5
MX - Messico 5
NL - Olanda 5
UA - Ucraina 5
AT - Austria 4
CH - Svizzera 4
ES - Italia 4
LT - Lituania 4
MY - Malesia 4
DK - Danimarca 3
PK - Pakistan 3
AR - Argentina 2
BD - Bangladesh 2
ID - Indonesia 2
IQ - Iraq 2
KR - Corea 2
ME - Montenegro 2
NO - Norvegia 2
SA - Arabia Saudita 2
SC - Seychelles 2
ZA - Sudafrica 2
BN - Brunei Darussalam 1
HU - Ungheria 1
IM - Isola di Man 1
MT - Malta 1
NG - Nigeria 1
PA - Panama 1
PH - Filippine 1
RS - Serbia 1
TN - Tunisia 1
TR - Turchia 1
VE - Venezuela 1
Totale 4.623
Salva come PNG Salva come JPEG
Città #
Chandler 766
Dublin 476
Singapore 309
Princeton 234
Jacksonville 190
Ashburn 170
Altamura 114
Dong Ket 93
Wilmington 85
Santa Clara 75
Ann Arbor 57
Chieti 42
Los Angeles 40
Falls Church 27
Rome 27
Taranto 19
Norwalk 17
Brussels 16
Teramo 16
London 15
Pune 12
New York 11
Xitun 11
Cluj-Napoca 10
Guangzhou 10
Edinburgh 9
Moscow 9
Helsinki 8
Sofia 8
Washington 8
Frankfurt am Main 7
Munich 7
Toronto 7
Chicago 6
Guglionesi 6
Tehran 6
Bologna 5
Chiang Mai 5
Dallas 5
Milan 5
San Jose 5
Seattle 5
Woodbridge 5
Bari 4
Beijing 4
Hangzhou 4
Kuala Lumpur 4
Shanghai 4
Stockholm 4
Tokyo 4
Copenhagen 3
Hefei 3
Kunming 3
Luxembourg 3
Montale 3
Multan 3
Pescara 3
Taipei 3
Termoli 3
Zagreb 3
Zurich 3
Alexander 2
Amsterdam 2
Andover 2
Atlanta 2
Baghdad 2
Bengaluru 2
Boardman 2
Cairo 2
Central 2
Cologne 2
Corvallis 2
Croydon 2
Dhaka 2
Echt 2
Fairfield 2
Fremont 2
Greccio 2
Guadalajara 2
Hamburg 2
Handan 2
Hong Kong 2
Houston 2
Hyderabad 2
Jati 2
Jeddah 2
Johannesburg 2
La Plata 2
Lappeenranta 2
Madrid 2
Maranello 2
Milton Keynes 2
Montreal 2
Mountain View 2
Nanjing 2
Nanning 2
Oslo 2
Ottawa 2
Parma 2
Passaic 2
Totale 3.097
Salva come PNG Salva come JPEG
Nome #
Assessment of crohn’s disease activity: Magnetic resonance enterography in comparison with clinical and endoscopic evaluations 95
13C-octanoic acid breath test to study gastric emptying time 93
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 87
Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis 84
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): Preliminary results from a retrospective cohort study 83
Akkermansia muciniphila: Key player in metabolic and gastrointestinal disorders 71
Bacillus clausii and gut homeostasis: state of the art and future perspectives 68
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 67
Characterization of sarcopenia in an IBD population attending an Italian gastroenterology tertiary center 62
Bacillus clausii for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials 59
Proteobacteria: A common factor in human diseases 59
Commensal Clostridia: Leading players in the maintenance of gut homeostasis 58
Tricks for interpreting and making a good report on hydrogen and 13C breath tests 57
The gastrointestinal microbiome - Functional interference between stomach and intestine 57
European Crohn's and colitis organisation topical review on treatment withdrawal ['exit strategies'] in inflammatory bowel disease 56
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 55
Role of yeasts in healthy and impaired gut microbiota: The gut mycome 55
Ulcerative colitis 55
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 55
Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila 54
Role of Helicobacter pylori infection on nutrition and metabolism 54
Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 54
Gut microbiota and inflammatory bowel disease: So far so gut! 53
Food components and dietary habits: Keys for a healthy gut microbiota composition 53
The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease 53
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 52
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 52
Dietary magnesium alleviates experimental murine colitis through upregulation of the transient receptor potential melastatin 6 channel 51
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises from a First Meta-Analysis 51
Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice 50
Flexible colonoscopy in mice to evaluate the severity of colitis and colorectal tumors using a validated endoscopic scoring system 50
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 50
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. Pylori infection 50
Bacteriocins and bacteriophages: Therapeutic weapons for gastrointestinal diseases? 50
Actinobacteria: A relevant minority for the maintenance of gut homeostasis 50
Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: A multidisciplinary management experience 49
Commentary to “safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease” 49
Microbiota and inflammatory bowel disease: An update 49
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders 49
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 49
Gut microbiota modulation and mucosal immunity: Focus on Rifaximin 48
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 48
The gut barrier: New acquisitions and therapeutic approaches 47
Gut Virome and Inflammatory Bowel Disease 47
IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair 47
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? 47
Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment 47
Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats 46
Considering gut microbiota disturbance in the management of Helicobacter pylori infection 46
Intestinal permeability in physiological and pathological conditions: Major determinants and assessment modalities 45
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 45
Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions 45
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: Where we stand and future perspectives 45
Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea 45
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 45
Relationship between oral microbiota and periodontal disease: A systematic review 44
Opposing functions of classic and novel IL-1 family members in gut health and disease 44
A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis 44
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 44
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 44
Prevalence of severe irritable bowel syndrome among Italian adults. A meta-analysis 43
Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries 43
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for ‘gut barrier protectors’ in IBD? 43
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications 43
Beyond the HLA Genes in Gluten-Related Disorders 42
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 42
The use of anti-spasmodics in the treatment of irritable bowel syndrome: Focus on otilonium bromide 41
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 41
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 41
Assessment of neurological manifestations in hospitalized patients with COVID-19 41
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 41
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 40
Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease 39
Can we predict the efficacy of anti-TNF-α agents? 39
Coeliac disease under a microscope: Histological diagnostic features and confounding factors 39
The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors 38
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 38
Epithelial-specific Toll-like Receptor (TLR)5 Activation Mediates Barrier Dysfunction in Experimental Ileitis 37
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 37
Fecal transplantation for ulcerative colitis: current evidence and future applications 37
Intestinal gas production and gastrointestinal symptoms: from pathogenesis to clinical implication 36
Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals 36
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 35
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis 35
Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases 34
Bariatric procedures and microbiota: patient selection and outcome prediction 34
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation 33
The use of probiotics in different phases of diverticular disease 32
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center 32
Gut microbial flora, prebiotics, and probiotics in IBD: Their current usage and utility 31
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice 29
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 29
Coordinated Multi-Language Translation of A Validated Symptom Questionnaire for Carbohydrate Intolerances: A Practical Structured Procedure 28
The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease 28
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 27
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 27
Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: The Picture Is Taking Shape 25
Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: An update 25
Gut microbiota during dietary restrictions: New insights in non-communicable diseases 24
European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus 23
Totale 4.669
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.521
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.521
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021782 235 4 165 34 59 135 12 10 10 6 16 96
2021/2022705 53 3 3 118 20 16 11 28 54 39 60 300
2022/20231.882 241 337 89 224 95 348 120 143 169 18 81 17
2023/2024849 53 36 47 51 36 186 235 87 14 37 13 54
2024/2025890 158 348 191 54 36 103 0 0 0 0 0 0
Totale 5.108